Literature DB >> 24711162

Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module.

David I Rosenthal1, Tito R Mendoza, Clifton D Fuller, Katherine A Hutcheson, X Shelley Wang, Ehab Y Hanna, Charles Lu, Adam S Garden, William H Morrison, Charles S Cleeland, G Brandon Gunn.   

Abstract

BACKGROUND: A prospective longitudinal study to profile patient-reported symptoms during radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) for head and neck cancer was performed. The goals were to understand the onset and trajectory of specific symptoms and their severity, identify clusters, and facilitate symptom interventions and clinical trial design.
METHODS: Participants in this questionnaire-based study received RT or CCRT. They completed the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module before and weekly during treatment. Symptom scores were compared between treatment groups, and hierarchical cluster analysis was used to depict clustering of symptoms at treatment end. Variables believed to predict symptom severity were assessed using a multivariate mixed model.
RESULTS: Among the 149 patients studied, the majority (47%) had oropharyngeal tumors, and nearly one-half received CCRT. Overall symptom severity (P < .001) and symptom interference (P < .0001) became progressively more severe and were more severe for those receiving CCRT. On multivariate analysis, baseline Eastern Cooperative Oncology Group performance status (P < .001) and receipt of CCRT (P < .04) correlated with higher symptom severity. Fatigue, drowsiness, lack of appetite, problem with mouth/throat mucus, and problem tasting food were more severe for those receiving CCRT. Both local and systemic symptom clusters were identified.
CONCLUSIONS: The findings from this prospective longitudinal study identified a pattern of local and systemic symptoms, symptom clusters, and symptom interference that was temporally distinct and marked by increased magnitude and a shift in individual symptom rank order during the treatment course. These inform clinicians about symptom intervention needs, and are a benchmark for future symptom intervention clinical trials.
© 2014 American Cancer Society.

Entities:  

Keywords:  chemoradiotherapy; head and neck cancer; patient-reported outcomes; radiotherapy; symptoms

Mesh:

Year:  2014        PMID: 24711162      PMCID: PMC4095802          DOI: 10.1002/cncr.28672

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

Review 1.  Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): searching for standards.

Authors:  Charles S Cleeland; Jeff A Sloan
Journal:  J Pain Symptom Manage       Date:  2010-06       Impact factor: 3.612

Review 2.  The clinical significance of adaptation to changing health: a meta-analysis of response shift.

Authors:  Carolyn E Schwartz; Rita Bode; Nicholas Repucci; Janine Becker; Mirjam A G Sprangers; Peter M Fayers
Journal:  Qual Life Res       Date:  2006-09-26       Impact factor: 4.147

3.  Importance of patient examination to clinical quality assurance in head and neck radiation oncology.

Authors:  David I Rosenthal; Joshua A Asper; Jerry L Barker; Adam S Garden; K S Clifford Chao; William H Morrison; Randal S Weber; K Kian Ang
Journal:  Head Neck       Date:  2006-11       Impact factor: 3.147

4.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

5.  Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module.

Authors:  David I Rosenthal; Tito R Mendoza; Mark S Chambers; Joshua A Asper; Ibrahima Gning; Merrill S Kies; Randal S Weber; Jan S Lewin; Adam S Garden; K Kian Ang; Xin S Wang; Charles S Cleeland
Journal:  Head Neck       Date:  2007-10       Impact factor: 3.147

Review 6.  Core outcome domains for chronic pain clinical trials: IMMPACT recommendations.

Authors:  Dennis C Turk; Robert H Dworkin; Robert R Allen; Nicholas Bellamy; Nancy Brandenburg; Daniel B Carr; Charles Cleeland; Raymond Dionne; John T Farrar; Bradley S Galer; David J Hewitt; Alejandro R Jadad; Nathaniel P Katz; Lynn D Kramer; Donald C Manning; Cynthia G McCormick; Michael P McDermott; Patrick McGrath; Steve Quessy; Bob A Rappaport; James P Robinson; Mike A Royal; Lee Simon; Joseph W Stauffer; Wendy Stein; Jane Tollett; James Witter
Journal:  Pain       Date:  2003-12       Impact factor: 6.961

Review 7.  Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation.

Authors:  Nuran Senel Bese; Jolyon Hendry; Branislav Jeremic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-04-30       Impact factor: 7.038

8.  The M. D. Anderson symptom inventory-head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis.

Authors:  David I Rosenthal; Tito R Mendoza; Mark S Chambers; V Shannon Burkett; Adam S Garden; Amy C Hessell; Jan S Lewin; K Kian Ang; Merrill S Kies; Ibrahima Gning; Xin S Wang; Charles S Cleeland
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-22       Impact factor: 7.038

Review 9.  Systemic and global toxicities of head and neck treatment.

Authors:  Barbara A Murphy; Jill Gilbert; Sheila H Ridner
Journal:  Expert Rev Anticancer Ther       Date:  2007-07       Impact factor: 4.512

Review 10.  NIH State-of-the-Science Statement on symptom management in cancer: pain, depression, and fatigue.

Authors: 
Journal:  NIH Consens State Sci Statements       Date:  2002 Jul 15-17
View more
  44 in total

1.  Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes.

Authors:  Terence T Sio; Huei-Kai Lin; Qiuling Shi; G Brandon Gunn; Charles S Cleeland; J Jack Lee; Mike Hernandez; Pierre Blanchard; Nikhil G Thaker; Jack Phan; David I Rosenthal; Adam S Garden; William H Morrison; C David Fuller; Tito R Mendoza; Radhe Mohan; Xin Shelley Wang; Steven J Frank
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-02-18       Impact factor: 7.038

2.  Validity of patient-reported swallowing and speech outcomes in relation to objectively measured oral function among patients treated for oral or oropharyngeal cancer.

Authors:  R N P M Rinkel; I M Verdonck-de Leeuw; R de Bree; N K Aaronson; C R Leemans
Journal:  Dysphagia       Date:  2015-01-28       Impact factor: 3.438

3.  Brainstem dose is associated with patient-reported acute fatigue in head and neck cancer radiation therapy.

Authors:  Matthew J Ferris; Jim Zhong; Jeffrey M Switchenko; Kristin A Higgins; Richard J Cassidy; Mark W McDonald; Bree R Eaton; Kirtesh R Patel; Conor E Steuer; H Michael Baddour; Andrew H Miller; Deborah W Bruner; Canhua Xiao; Jonathan J Beitler
Journal:  Radiother Oncol       Date:  2017-08-18       Impact factor: 6.280

4.  Initial Feasibility and Clinical Implementation of Daily MR-Guided Adaptive Head and Neck Cancer Radiation Therapy on a 1.5T MR-Linac System: Prospective R-IDEAL 2a/2b Systematic Clinical Evaluation of Technical Innovation.

Authors:  Brigid A McDonald; Sastry Vedam; Jinzhong Yang; Jihong Wang; Pamela Castillo; Belinda Lee; Angela Sobremonte; Sara Ahmed; Yao Ding; Abdallah S R Mohamed; Peter Balter; Neil Hughes; Daniela Thorwarth; Marcel Nachbar; Marielle E P Philippens; Chris H J Terhaard; Daniel Zips; Simon Böke; Musaddiq J Awan; John Christodouleas; Clifton D Fuller
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-12-16       Impact factor: 7.038

5.  Electronic patient-reported outcomes and toxicities during radiotherapy for head-and-neck cancer.

Authors:  Joshua R Niska; Michele Y Halyard; Angelina D Tan; Pamela J Atherton; Samir H Patel; Jeff A Sloan
Journal:  Qual Life Res       Date:  2017-02-28       Impact factor: 4.147

6.  Grading Dysphagia as a Toxicity of Head and Neck Cancer: Differences in Severity Classification Based on MBS DIGEST and Clinical CTCAE Grades.

Authors:  Ryan P Goepfert; Jan S Lewin; Martha P Barrow; Carla L Warneke; Clifton D Fuller; Stephen Y Lai; Randal S Weber; Katherine A Hutcheson
Journal:  Dysphagia       Date:  2017-08-23       Impact factor: 3.438

7.  Linguistic Validation of the Turkish Version of the M.D. Anderson Symptom Inventory - Head and Neck Cancer Module.

Authors:  G Brandon Gunn; Banu Atalar; Tito R Mendoza; Charles S Cleeland; Uğur Selek; Enis Özyar; David I Rosenthal
Journal:  Balkan Med J       Date:  2016-05-01       Impact factor: 2.021

8.  Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: Dose-volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy.

Authors: 
Journal:  Radiother Oncol       Date:  2016-02-17       Impact factor: 6.280

9.  Recurrent oropharyngeal cancer after organ preserving treatment: pattern of failure and survival.

Authors:  M de Ridder; Z A R Gouw; J J Sonke; A Navran; B Jasperse; J Heukelom; M E T Tesselaar; W M C Klop; M W M van den Brekel; Abrahim Al-Mamgani
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-09       Impact factor: 2.503

10.  Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation.

Authors:  Stuart E Samuels; Yebin Tao; Teresa Lyden; Marc Haxer; Matthew Spector; Kelly M Malloy; Mark E Prince; Carol R Bradford; Francis P Worden; Matthew Schipper; Avraham Eisbruch
Journal:  Oral Oncol       Date:  2016-01-06       Impact factor: 5.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.